+278.7%
AMD vs MRNA
+9.2%
+269.4%
-65.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.3% | -0.9% | +8.2% | +7.4% |
| 7D | +13.1% | -3.8% | +16.9% | +13.7% |
| 30D | -7.0% | +16.4% | -23.3% | -8.1% |
| 3M | +16.6% | +310.6% | -294.0% | -5.4% |
| 6M | +20.5% | +370.3% | -349.8% | -6.8% |
| YTD | +158.2% | +743.3% | -585.1% | +72.2% |
| 1Y | +132.8% | +841.7% | -708.9% | +50.8% |
| 3Y | +366.2% | +255.0% | +111.2% | +243.4% |
| 5Y | +278.7% | +10.1% | +268.5% | +230.6% |
| All | +278.7% | +9.2% | +269.4% | +230.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling